REDWOOD CITY, Calif., June 1, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) previously announced on May 30, 2009, clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society for Clinical Oncology (ASCO) being held May 29 to June 2, 2009, at the Orange County Convention Center in Orlando, FL.
